Opendata, web and dolomites

NPsVLCD SIGNED

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NPsVLCD project word cloud

Explore the words cloud of the NPsVLCD project. It provides you a very rough idea of what is the project "NPsVLCD" about.

resistance    overarching    compliance    antiparasitic    dependent    dogma    critically    cd    candidates    million    action    pharmacokinetic    malaria    parasitologist    strategies    record    collaborations    tempone    refinement    expert    parasitic    investment    contrast    patient    read    thereby    prominent    affe    despite    progress    largely    clinical    modular    frontline    andre    potentially    evaluation    series    concise    additionally    urgently    bioactivity    made    efficiency    examples    track    worldwide    pharmacophores    trials    time       ignored    compound    parasite    pharmacologist    preclinical    disease    pharmacophore    12    leishmaniasis    modification    artemisinin    therapeutic    convergent    dynamic    couple    alkaloid    amphotericin    limited    visceral    accessibility    vl    mode    severe    synthesis    central    modes    multidisciplinary    limitations    informing    chemistry    leishmaniases    treatments    prof    therapies    natural    exploration    feedback    families    compounds    people    kevin    suffer    drugs    identification    synthetic    few    leads    chagas    progressed    structurally   

Project "NPsVLCD" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD 

Organization address
address: WELLINGTON SQUARE UNIVERSITY OFFICES
city: OXFORD
postcode: OX1 2JD
website: www.ox.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 212˙933 €
 EC max contribution 212˙933 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) coordinator 212˙933.00

Map

 Project objective

The development of new therapies for leishmaniases (which affeThe development of new therapies for visceral leishmaniasis (affects ~12 million people worldwide) and Chagas disease (~6-7 million people worldwide) is critically dependent on the identification of novel pharmacophores with new modes of action. Current treatments suffer from severe side effects, high cost, patient compliance issues, and emerging resistance; as such, new therapeutic leads are urgently required. Despite significant investment, limited progress has been made with research into new 'synthetic' drugs: no candidates are in clinical trials (although two compounds have recently progressed to preclinical evaluation for VL). In contrast, research into natural product-derived drugs has been largely ignored, despite their track record as frontline treatments for VL (amphotericin B) and the most prominent parasitic disease, malaria (artemisinin). In this project, we challenge this dogma through the exploration of a series of structurally-related alkaloid natural product families, where highly promising antiparasitic bioactivity has been observed in the few examples studied. The selection of these families is additionally based on their accessibility through concise, modular and convergent synthetic strategies, which facilitate modification. We couple this central focus of synthetic chemistry with collaborations to evaluate bioactivity (with expert parasitologist Prof Andre Tempone), and identify pharmacokinetic/dynamic limitations (with expert pharmacologist Prof Kevin Read), thereby informing analogue refinement and synthesis. This multidisciplinary approach will greatly enhance the impact of the synthetic chemistry work by providing 'real-time' feedback into compound design, enhancing project efficiency and progress. Our overarching, long term impact objective is to identify a new pharmacophore (and potentially new parasite target / mode of action) for the potential development of VL/CD therapies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NPSVLCD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NPSVLCD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

RETHEIR (2019)

The return of the heirs

Read More  

LYSOKIN (2020)

Architecture and regulation of PI3KC2β lipid kinase complex for nutrient signaling at the lysosome

Read More  

InvADeRS (2019)

Investigating the Activity of transposon Derived Regulatory Sequences in the placenta

Read More